1. Pink Sheet

Pfizer's New Structure Reinforces Potential Split

Organizing commercial operations under Allergan's Brent Saunders is not a preview of an eventual corporate split, but leaves options open, Pfizer says.

Pfizer Inc. and Allergan PLCnamed the leadership team for the combined company Feb. 8, the highlights of which include the departure of Pfizer’s Group President-Global Innovative Pharma Geno Germano and the promotion of Allergan Executive VP Bill Meury. As expected, the leadership team includes two groups, one reporting to Chairman and CEO Ian Read and the other reporting to Brent Saunders, who will be president and chief operating officer.

Pfizer announced that effective immediately and through the deal's closing, expected during the second half of 2016, Albert Bourla, currently group president of Pfizer's Vaccines, Oncology and Consumer (VOC) unit,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Agency Leadership

More from Pink Sheet

MAHA Commission Outlines Enhanced Research On Drug Safety In Children

 
• By Cathy Kelly

Research would include initiatives on reproducing industry-sponsored studies, postmarket surveillance, and studies of long-term neurodevelopmental and metabolic outcomes for commonly prescribed pediatric drugs.

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.